Study on Clinical Features, Treatment Mode and Survival of Sarcoma
- Conditions
- Sarcoma
- Registration Number
- NCT05453409
- Lead Sponsor
- Henan Cancer Hospital
- Brief Summary
The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.
- Detailed Description
This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 6000
No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes.
Complete follow-up data.
No clear pathology. Incomplete follow-up data.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival Up to approximately 24months Progression-free survival is defined as time from enrollment to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment.
Overall survival Up to approximately 120months Time from pathological diagnosis to death
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Bone and Soft Tissue ,Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China